FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023183409> ?p ?o ?g. }

• W2023183409 endingPage "143" @default.
• W2023183409 startingPage "137" @default.
• W2023183409 abstract "Background: To assess the lipid-lowering effects and safety of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Methods: We performed a randomized, open-label, parallel-design, active-controlled, study in eight centers in the United States. We enrolled 108 patients with total cholesterol (TC) of ≥200 mg/dL, serum triglycerides (TG) ≥200 and ≤800 mg/dL, and apolipoprotein B (apo B) ≥110 mg/dL. Patients were randomly assigned to receive atorvastatin 10 mg once daily (n = 55) or immediate-release niacin 1 g three times daily for 12 weeks (n = 53). Patients were stratified based on low-density lipoprotein cholesterol (LDL-C): Patients with LDL-C ≥135 mg/dL were considered to have combined hyperlipidemia and patients with LDL-C <135 mg/dL were considered to have isolated hypertriglyceridemia. The primary outcome measure was percent change from baseline in LDL-C. Other lipid levels were evaluated as secondary parameters. Results: Atorvastatin reduced LDL-C 30% and TC 26% from baseline, and increased high-density lipoprotein cholesterol (HDL-C) 4%. Total TG were reduced 17%. Niacin reduced LDL-C 2%, TC 7%, increased HDL-C 25%, and reduced total TG 29% from baseline. There was a significant difference in LDL-C reduction, the primary efficacy parameter, between the two treatment groups (P <0.05, favoring atorvastatin), as well as a significant difference in the improvement in HDL-C (P <0.05, favoring niacin). The effect of atorvastatin was relatively consistent between patients with combined hyperlipidemia and isolated hypertriglyceridemia, whereas there was more variability between these strata in the niacin treatment group. Atorvastatin was better tolerated than niacin. Conclusion: Atorvastatin may allow patients with combined hyperlipidemia to be treated with monotherapy and offers an efficacious and well-tolerated alternative to niacin for the treatment of patients with isolated hypertriglyceridemia." @default.
• W2023183409 created "2016-06-24" @default.
• W2023183409 creator A5032891959 @default.
• W2023183409 creator A5036984625 @default.
• W2023183409 creator A5054320288 @default.
• W2023183409 creator A5061030125 @default.
• W2023183409 creator A5088270258 @default.
• W2023183409 creator A5089357443 @default.
• W2023183409 date "1998-02-01" @default.
• W2023183409 modified "2023-09-26" @default.
• W2023183409 title "A Randomized Trial of the Effects of Atorvastatin and Niacin in Patients with Combined Hyperlipidemia or Isolated Hypertriglyceridemia" @default.
• W2023183409 cites W1860487341 @default.
• W2023183409 cites W1988179941 @default.
• W2023183409 cites W1989258056 @default.
• W2023183409 cites W1991160610 @default.
• W2023183409 cites W1999937176 @default.
• W2023183409 cites W2000228832 @default.
• W2023183409 cites W2001923460 @default.
• W2023183409 cites W2004838889 @default.
• W2023183409 cites W2006705370 @default.
• W2023183409 cites W2007577002 @default.
• W2023183409 cites W2037328752 @default.
• W2023183409 cites W2044397157 @default.
• W2023183409 cites W2046524469 @default.
• W2023183409 cites W2048781113 @default.
• W2023183409 cites W2058514346 @default.
• W2023183409 cites W2067529252 @default.
• W2023183409 cites W2070547707 @default.
• W2023183409 cites W2077901889 @default.
• W2023183409 cites W2092903282 @default.
• W2023183409 cites W2093667080 @default.
• W2023183409 cites W2094172628 @default.
• W2023183409 cites W2103851590 @default.
• W2023183409 cites W2106097609 @default.
• W2023183409 cites W2106536809 @default.
• W2023183409 cites W2118310760 @default.
• W2023183409 cites W2123420731 @default.
• W2023183409 cites W2145117630 @default.
• W2023183409 cites W2145970366 @default.
• W2023183409 cites W2152651023 @default.
• W2023183409 cites W2155238815 @default.
• W2023183409 cites W2160760242 @default.
• W2023183409 cites W2161906002 @default.
• W2023183409 cites W4249750268 @default.
• W2023183409 cites W4293872614 @default.
• W2023183409 doi "https://doi.org/10.1016/s0002-9343(97)00311-2" @default.
• W2023183409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9528731" @default.
• W2023183409 hasPublicationYear "1998" @default.
• W2023183409 type Work @default.
• W2023183409 sameAs 2023183409 @default.
• W2023183409 citedByCount "73" @default.
• W2023183409 countsByYear W20231834092012 @default.
• W2023183409 countsByYear W20231834092013 @default.
• W2023183409 countsByYear W20231834092014 @default.
• W2023183409 countsByYear W20231834092015 @default.
• W2023183409 countsByYear W20231834092016 @default.
• W2023183409 countsByYear W20231834092017 @default.
• W2023183409 countsByYear W20231834092020 @default.
• W2023183409 crossrefType "journal-article" @default.
• W2023183409 hasAuthorship W2023183409A5032891959 @default.
• W2023183409 hasAuthorship W2023183409A5036984625 @default.
• W2023183409 hasAuthorship W2023183409A5054320288 @default.
• W2023183409 hasAuthorship W2023183409A5061030125 @default.
• W2023183409 hasAuthorship W2023183409A5088270258 @default.
• W2023183409 hasAuthorship W2023183409A5089357443 @default.
• W2023183409 hasBestOaLocation W20231834091 @default.
• W2023183409 hasConcept C126322002 @default.
• W2023183409 hasConcept C134018914 @default.
• W2023183409 hasConcept C168563851 @default.
• W2023183409 hasConcept C2776919658 @default.
• W2023183409 hasConcept C2777482532 @default.
• W2023183409 hasConcept C2778163477 @default.
• W2023183409 hasConcept C2778913445 @default.
• W2023183409 hasConcept C2779091943 @default.
• W2023183409 hasConcept C2780072125 @default.
• W2023183409 hasConcept C2780092750 @default.
• W2023183409 hasConcept C555293320 @default.
• W2023183409 hasConcept C62746215 @default.
• W2023183409 hasConcept C71924100 @default.
• W2023183409 hasConcept C90924648 @default.
• W2023183409 hasConceptScore W2023183409C126322002 @default.
• W2023183409 hasConceptScore W2023183409C134018914 @default.
• W2023183409 hasConceptScore W2023183409C168563851 @default.
• W2023183409 hasConceptScore W2023183409C2776919658 @default.
• W2023183409 hasConceptScore W2023183409C2777482532 @default.
• W2023183409 hasConceptScore W2023183409C2778163477 @default.
• W2023183409 hasConceptScore W2023183409C2778913445 @default.
• W2023183409 hasConceptScore W2023183409C2779091943 @default.
• W2023183409 hasConceptScore W2023183409C2780072125 @default.
• W2023183409 hasConceptScore W2023183409C2780092750 @default.
• W2023183409 hasConceptScore W2023183409C555293320 @default.
• W2023183409 hasConceptScore W2023183409C62746215 @default.
• W2023183409 hasConceptScore W2023183409C71924100 @default.
• W2023183409 hasConceptScore W2023183409C90924648 @default.
• W2023183409 hasIssue "2" @default.
• W2023183409 hasLocation W20231834091 @default.
• W2023183409 hasLocation W20231834092 @default.
• W2023183409 hasOpenAccess W2023183409 @default.

• next